Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.

Research into Cold Cancers Heating Up

Activation and expansion are essential for success in both autologous and allogeneic therapies.

Development of Gamma-Delta T-Cell Therapies

Continuous manufacturing and a quality-by-design development approach are a natural fit.

QbD for Small-Molecule Continuous Process Development

Topic

Feliza Mirasol is the science editor for 

Articles

CDC panel shifts vaccine policy by discouraging combined MMRV shot for young children due to increased febrile seizure risk.

CDC Panel’s Vote Separates MMRV Shot and What That Means

Patrick Lavery is an Editor for the MJH Life Sciences brands 

. Previously at MJH, he filled the same role for 

Videos

In this exclusive Drug Digest video, Steve Barr from SK pharmteco and Prasad Raje from LGM Pharma explore how supply chain pressures, sustainability, and AI adoption are reshaping small molecule development and excipient use in pharma.

Drug Digest: Small Molecules, APIs, and Excipients—Trends, Challenges, and Opportunities

Dan Williams, CEO of SynaptixBio emphasizes how small biotechs are using genetic research and partnerships to accelerate rare disease innovation in the final installment of his interview.

The Role of Genetic Advances and Partnerships in Rare Disease Drug Development (Part 3)

The Phase IIa study will test HTL0039732 in combination with immunotherapy to boost responses in resistant solid tumors and broaden treatment choices.

Cancer Research UK Partners with Nxera on Next-Stage Trial for HTL0039732 

Corstasis Therapeutics plans to launch the product in the United States in the fourth quarter of 2025.

FDA Approves Cortasis Nasal Spray, Enbumyst, for Edema

Cheryl Barton is director of PharmaVision, 

Novo Nordisk’s Wegovy will be competing with Madrigal Pharmaceuticals’ Rezdiffra in the metabolic dysfunction-associated steatohepatitis arena. 

Competition in MASH Is Heating Up as GLP-1s Gate-Crash the Party

The 2024 edition of the annual conference, held in Milan, attracted more than 59,000 professionals from across the bio/pharmaceutical landscape.

CPHI Frankfurt Expected to Draw More Than 60,000 Attendees in October

The two organizations are collaborating on an integrated translational biology platform for the development of radiopharmaceuticals.

Medicines Discovery Catapult and Crown Bioscience Create Alliance for Radiopharmaceuticals

Mike Hennessy Jr. is the Chairman and CEO of 

Scientific discovery, technological evolution, and market demands are constantly reshaping the landscape.

Building Resilience and Precision in Pharma Development

Chris Spivey is director of Industry Relations and Strategic Partnership, MJH Life Sciences.

Aaron Cowley, Recipharm Advanced Bio; Renee Hart, LumaCyte; and Vibha Jawa, EpiVax, go behind the headlines to delve deeper into recent market deals driven by Big Pharma patent cliffs and the complex manufacturing of ATMPs. 

Behind the Headlines Episode 24: Surging Implementation of Sequence Event Reporting in CMC Analytics, Billion Dollar Deals Push Further Consolidation or Collapse, and an Analytics Wish List